Clinical Trial Detail

NCT ID NCT01688492
Title Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Prednisone

Ipilimumab

Age Groups: adult

No variant requirements are available.